Furnival-Adams, Joanna https://orcid.org/0000-0002-2451-0107
Houana, Amelia
Nicolas, Patricia
Montaña, Julia
Martinho, Samuel
Casellas, Aina
Mundaca, Hansel
Mbanze, Jenisse
Soares, Arlindo
Imputiua, Saimado
Ruiz-Castillo, Paula
Ribes, Marta
Sanz, Almudena
Salé, Mussa Mamudo
Macucha, Antonio
Elobolobo, Eldo
Vegove, Vegovito
Mutepa, Victor
Munguambe, Humberto
Xerinda, Aida
Materula, Felisbela
Rabinovich, Regina
Saute, Francisco
Chaccour, Carlos
Clinical trials referenced in this document:
Documents that mention this clinical trial
Collateral benefits of ivermectin mass drug administration designed for malaria against headlice in Mopeia, Mozambique: a cluster randomised controlled trial
https://doi.org/10.1186/s40249-025-01290-z
BOHEMIA a cluster randomized trial to assess the impact of an endectocide-based one health approach to malaria in Mozambique: baseline demographics and key malaria indicators
https://doi.org/10.1186/s12936-023-04605-3
Funding for this research was provided by:
Unitaid (BOHEMIA)
Article History
Received: 7 October 2024
Accepted: 2 March 2025
First Online: 27 March 2025
Declarations
:
: The study protocol was approved by the Internal Scientific Committee and Institutional Review board from the Centro de Investigacao em Saude de Manhica (Ref: CIBS-CISM/004/2021), Hospital Clinic of Barcelona Clinical Research Ethics Committee (ISGlobal’s Internal Review Board) (Ref: HCB/2019/0938) and The Ethics Research Committee of the WHO (Protocol ID: ERC.0003265). Written consent was obtained from all adult participants, and assent was obtained from parent/guardian’s of children aged between 12–17. For children under 12, consent was obtained from their parent/guardian. All records that contained names or other personal identifiers, such as locator forms, participant identification code list and informed consent forms, were stored separately from study records identified by code number.
: Not applicable.
: The authors declare that they have no competing interests.